Table 3.

CATAP treatment and treatment response in enrolled cohort

Patient number	Gender	Age	Tumor origin	Pembro i.v. before	Number of intrahepatic lesions	Diameter (mm)	Extrahepatic metastasis	Cycles in combined stage	Reason for discontinuity in combined stagea	Cycles in infusion stage	Reason for discontinuity in infusion stagea	Best treatment Response
1	Female	62	Cutaneous	No	> 20	24	Present	3	Self	2	Self	Partial response
2	Male	43	Uveal	No	> 20	21	Present	1	disease progression	0	Disease progression	Progression
3	Male	53	Cutaneous	No	> 20	42	Present	3	Disease progression	1	Disease progression	Progression
4	Male	76	Cutaneous	No	4–20	55	Present	2	Self	0	Self	Stable disease
5	Female	43	Uveal	No	> 20	30	Present	3	Self	6	Self	Partial response
6	Female	68	Uveal	No	4–20	13	Absent	2	Disease progression	2	Disease progression	Progression
7	Female	32	Cutaneous	Yes	> 20	60	Present	2	Self	0	Self	Stable disease
8	Male	34	Cutaneous	Yes	4–20	13	Present	2	Self	2	Self	Partial response
9	Female	57	Uveal	No	4–20	52	Present	4	–	3	Disease progression	Stable disease
10	Female	55	Uveal	No	4–20	65	Absent	3	High PS score	2	Disease progression	Progression
11	Male	53	Cutaneous	Yes	4–20	32	Present	2	Disease progression	1	Disease progression	Progression
12	Female	53	Uveal	No	> 20	60	Present	1	High PS score	0	High PS score	Progression
13	Male	54	Cutaneous	Yes	> 20	17	Present	2	Disease progression	0	Disease progression	Progression
14	Male	33	Cutaneous	Yes	> 20	30	Present	1	Self	1	Disease progression	Progression
15	Male	56	Cutaneous	Yes	> 20	27	Present	2	Self	8	CR achieved	Complete response

^aSelf refers to discontinuity of treatment based on patients’ requests